title: The M-PMV cytoplasmic targeting-retention signal directs nascent Gag polypeptides to a pericentriolar region of the cell.
abstract: Intracytoplasmic protein targeting in mammalian cells is critical for organelle function as well as virus assembly, but the signals that mediate it are poorly defined. We show here that Mason-Pfizer monkey virus specifically targets Gag precursor proteins to the pericentriolar region of the cytoplasm in a microtubule dependent process through interactions between a short peptide signal, known as the cytoplasmic targeting-retention signal, and the dynein/dynactin motor complex. The Gag molecules are concentrated in pericentriolar microdomains, where they assemble to form immature capsids. Depletion of Gag from this region by cycloheximide treatment, coupled with the presence of ribosomal clusters that are in close vicinity to the assembling capsids, suggests that the dominant N-terminal cytoplasmic targeting-retention signal functions in a cotranslational manner. Transport of the capsids out of the pericentriolar assembly site requires the env-gene product, and a functional vesicular transport system. A single point mutation that renders the cytoplasmic targeting-retention signal defective abrogates pericentriolar targeting of Gag molecules. Thus the previously defined cytoplasmic targeting-retention signal appears to act as a cotranslational intracellular targeting signal that concentrates Gag proteins at the centriole for assembly of capsids.
authors.affiliation: Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Sfakianos
authors.forename: Rachel A
authors.initials: RA
authors.lastname: LaCasse
authors.forename: Eric
authors.initials: E
authors.lastname: Hunter
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D019556:COS Cells; D002213:Capsid / Q000378:metabolism / Q000648:ultrastructure; D002460:Cell Line; D018385:Centrosome / Q000378:metabolism* / Q000648:ultrastructure; D002522:Chlorocebus aethiops; D003513:Cycloheximide / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism* / Q000648:ultrastructure / Q000821:virology; D015686:Gene Products, env / Q000378:metabolism; D015683:Gene Products, gag / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D016093:Mason-Pfizer monkey virus / Q000378:metabolism / Q000502:physiology* / Q000648:ultrastructure; D008856:Microscopy, Fluorescence; D008870:Microtubules / Q000378:metabolism / Q000648:ultrastructure; D015739:Nocodazole / Q000494:pharmacology; D017354:Point Mutation; D011499:Protein Processing, Post-Translational; D021382:Protein Sorting Signals / Q000235:genetics / Q000502:physiology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D021381:Protein Transport; D019065:Virus Assembly
chemical_list: D000911:Antibodies, Monoclonal; D015686:Gene Products, env; D015683:Gene Products, gag; D021382:Protein Sorting Signals; D011500:Protein Synthesis Inhibitors; D003513:Cycloheximide; D015739:Nocodazole